Erratum: Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL (Genes and Immunity (2013) 14 (336-345) DOI: 10.1038/gene.2013.29);Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL

Genes and Immunity

Volumn 14, Issue 5, 2013, Pages 336-345

  Walsh, N C ^a   Alexander, K A ^b,c   Manning, C A ^d   Karmakar, S K ^d   Wang, J F ^e   Weyand, C M ^f   Pettit, A R ^b   Gravallese, E M ^d  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e GLAXOSMITHKLINE   (China)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammatory bone loss; RANKL; Secreted RANKL; T cells; TNFSF11

Indexed keywords

ISOPROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR;

ALTERNATIVE RNA SPLICING; ARTICLE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 84880919124     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2013.39     Document Type: Erratum

References (51)

1. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-3602.
2. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323.
3. Anjubault T, Martin J, Hubert FX, Chauvin C, Heymann D, Josien R. Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-kappaB ligand (RANK)-L by rat plasmacytoid dendritic cells 2012. PloS one 7: e33713.
4. Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM. RANKL/RANK-beyond bones. J Mol Med (Berl) 2011; 89: 647-656.
5. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997; 272: 25190-25194. (Pubitemid 27415705)
6. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186: 2075-2080. (Pubitemid 28013694)
7. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179. (Pubitemid 27507987)
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999; 25: 109-113. (Pubitemid 29322072)
9. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176. (Pubitemid 28180851)
10. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274: 13613-13618.
11. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 2000; 269: 532-536. (Pubitemid 30440335)
12. Lai FP, Cole-Sinclair M, Cheng WJ, Quinn JM, Gillespie MT, Sentry JW et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004; 126: 192-201. (Pubitemid 38961937)
13. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer research 2003; 63: 5438-5445. (Pubitemid 37139862)
14. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001. (Pubitemid 28433427)
15. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998; 246: 199-204. (Pubitemid 28413951)
16. Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998; 246: 337-341. (Pubitemid 28412599)
17. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256: 449-455. (Pubitemid 29301126)
18. Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 2002; 20: 337-344. (Pubitemid 40645655)
19. Vernal R, Dutzan N, Hernandez M, Chandia S, Puente J, Leon R et al. High expression levels of receptor activator of nuclear factor-kappa B ligand associated with human chronic periodontitis are mainly secreted by CD4+ T lymphocytes. J Periodontol 2006; 77: 1772-1780. (Pubitemid 44680243)
20. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Toz H et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 2007; 34: 370-376.
21. Sakellari D, Menti S, Konstantinidis A. Free soluble receptor activator of nuclear factor-kappab ligand in gingival crevicular fluid correlates with distinct pathogens in periodontitis patients. J Clin Periodontol 2008; 35: 938-943.
22. Silva MJ, Kajiya M, AlShwaimi E, Sasaki H, Hong J, Ok P et al. Bacteria-reactive immune response may induce RANKL-expressing T cells in the mouse periapical bone loss lesion. J Endod 2012; 38: 346-350.
23. Kreahling J, Graveley BR. The origins and implications of Aluternative splicing. Trends Genet 2004; 20: 1-4. (Pubitemid 38032814)
24. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309. (Pubitemid 129516268)
25. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265: 144-150.
26. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis and rheumatism 2000; 43: 250-258. (Pubitemid 30395732)
27. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis and rheumatism 2000; 43: 259-269. (Pubitemid 30395733)
28. Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin invest 2000; 106: R59-R67.
29. Jiang Y, Mehta CK, Hsu TY, Alsulaimani FF. Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. Infect Immun 2002; 70: 3143-3148. (Pubitemid 34564177)
30. Liu D, Xu JK, Figliomeni L, Huang L, Pavlos NJ, Rogers M et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med 2003; 11: 17-21.
31. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006; 169: 987-998. (Pubitemid 44411961)
32. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002; 100: 4615-4621. (Pubitemid 35429706)
33. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004; 104: 3722-3730. (Pubitemid 39564450)
34. Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001; 142: 1419-1426. (Pubitemid 32299669)
35. Ikeda T, Kasai M, Suzuki J, Kuroyama H, Seki S, Utsuyama M et al. Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis. J B C 2003; 278: 47217-47222. (Pubitemid 37452308)
36. Suzuki J, Ikeda T, Kuroyama H, Seki S, Kasai M, Utsuyama M et al. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 2004; 314: 1021-1027. (Pubitemid 38142386)
37. Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C et al. Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatology international 2008; 28: 987-993.
38. O'Brien CA. Control of RANKL gene expression. Bone 2010; 46: 911-919.
39. Bishop KA, Coy HM, Nerenz RD, Meyer MB, Pike JW. Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem 2011; 286: 20880-20891.
40. Bishop KA, Meyer MB, Pike JW. A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression. Mol Endocrinol 2009; 23: 2095-2110.
41. Takami M, Cho ES, Lee SY, Kamijo R, Yim M. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS letters 2005; 579: 832-838.
42. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT et al. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000; 141: 4711-4719. (Pubitemid 32055151)
43. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 2006; 26: 6453-6468. (Pubitemid 44277886)
44. Nerenz RD, Martowicz ML, Pike JW. An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3. Mol Endocrinol 2008; 22: 1044-1056. (Pubitemid 351629606)
45. Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 2006; 26: 6469-6486. (Pubitemid 44277887)
46. Kim S, Yamazaki M, Zella LA, Meyer MB, Fretz JA, Shevde NK et al. Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 2007; 103: 430-434. (Pubitemid 46401290)
47. Martowicz ML, Meyer MB, Pike JW. The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers. J Cell Biochem 2011; 112: 2030-2045.
48. Lee HL, Bae OY, Baek KH, Kwon A, Hwang HR, Qadir AS et al. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NFkappaB ligand in osteoblasts. Bone 2011; 49: 242-249.
49. Rossa C, Ehmann K, Liu M, Patil C, Kirkwood KL. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 2006; 26: 719-729. (Pubitemid 44934111)
50. Pfaffl MW. A new mathematical model for relative quantification in real-time RTPCR. Nucleic acids research 2001; 29: e45.
51. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 2006; 372: 92-102.